Arbutus Biopharma ( (ABUS) ) has provided an update.
Arbutus Biopharma reported its financial results for the fourth quarter and year-end 2024, alongside a corporate update. The company is undergoing significant restructuring, including a 57% workforce reduction and changes in executive leadership, to enhance financial and operational efficiency. It is focusing on accelerating the development of its cHBV treatment, imdusiran, while also defending its intellectual property through litigation. Arbutus has a strong financial position with $123 million in cash and investments, and expects 2025 to be transformative as it continues to advance its clinical trials and pipeline development.
More about Arbutus Biopharma
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is involved in the development of treatments for chronic hepatitis B virus (cHBV) and is actively working on advancing its pipeline, including the drug imdusiran.
YTD Price Performance: 1.82%
Average Trading Volume: 853,931
Technical Sentiment Signal: Hold
Current Market Cap: $638.6M
See more insights into ABUS stock on TipRanks’ Stock Analysis page.